SCHEMBL30011461

SCHEMBL30011461

CN(C)C1CCN(c2ccc(-c3ccc4ncn5c(c(C6CCOCC6)c(=O)n5C)c4c3)cc2F)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ATM Q13315 4/20 0.42
▸ ATR Q13535 3/20 0.42
▸ PIK3CA P42336 1/20 0.42
▸ MTOR P42345 1/20 0.42
▸ SYK P43405 2/20 0.40
▸ PIK3CD O00329 5/20 0.39
▸ CSF1R P07333 5/20 0.39
▸ CDK4 P11802 5/20 0.39
▸ CDK6 Q00534 5/20 0.39
▸ CCNK O75909 1/20 0.36
▸ CCNA2 P20248 1/20 0.36
▸ CDK2 P24941 1/20 0.36
▸ CDK7 P50613 1/20 0.36
▸ CDK9 P50750 1/20 0.36
▸ CCNH P51946 1/20 0.36
▸ CDK5 Q00535 1/20 0.36
▸ CDK5R1 Q15078 1/20 0.36
▸ PDE3B Q13370 3/20 0.36
▸ PDE3A Q14432 3/20 0.36
▸ MCHR1 Q99705 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30839640 0.92 ATM (0.41) ATMATRPIK3CAMTORSYK
SCHEMBL30012532 0.92 ATM (0.41) ATMATRPIK3CAMTORSYK
SCHEMBL30011050 0.91 MTOR (0.41) ATMATRPIK3CAMTORSYK
SCHEMBL29217588 0.85 ATM (0.48) ATMATRPIK3CAMTORSYK
SCHEMBL30012314 0.85 ATM (0.48) ATMATRPIK3CAMTORSYK
SCHEMBL30012169 0.83 MTOR (0.41) ATMATRPIK3CAMTORSYK
SCHEMBL30012789 0.81 MTOR (0.40) PIK3CAMTORSYKPIK3CDPDE3B
SCHEMBL30012579 0.80 MTOR (0.39) PIK3CAMTORSYKPIK3CDPDE3B
SCHEMBL30839660 0.78 PIK3CD (0.38) ATMPIK3CAMTORSYKPIK3CD
SCHEMBL22891687 0.76 IRAK4 (0.37) ATMATRPIK3CAMTORIRAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114026097-B Substituted pyrazoloquinazolinone compounds and uses thereof 上海瑛派药业有限公司 2024-02-23 — — CN claimed
US-20220259211-A1 SUBSTITUTED PYRAZOLOQUINAZOLINONE COMPOUNDS AND APPLICATION THEREOF Impact Therapeutics (Shanghai), Inc (CN) 2022-08-18 — — US claimed
CN-114026097-B Substituted pyrazoloquinazolinone compounds and uses thereof 上海瑛派药业有限公司 2024-02-23 — — CN disclosed
US-20220259211-A1 SUBSTITUTED PYRAZOLOQUINAZOLINONE COMPOUNDS AND APPLICATION THEREOF Impact Therapeutics (Shanghai), Inc (CN) 2022-08-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220259211-A1 SUBSTITUTED PYRAZOLOQUINAZOLINONE COMPOUNDS AND APPLICATION THEREOF CHEK1, CHEK2, ATM ATM 3/4885ATR 4/4885PIK3CA 381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback